drugset / Trial / NCT03947814
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are not yet on dialysis compared to adult participants with normal renal function (Part A). Optionally, to evaluate the PK in adult participants with mild and/or moderate renal impairment compared to adult participants with normal renal function (Part B).
Timeline
- Start
- 2019-07-02
- Primary completion
- 2020-09-09
- Completion
- 2020-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimodivir | Small molecule | 600 mg | Oral |